Underutilization of Warfarin Therapy in Elderly
Patients with Atrial Fibrillation – Fear or False Sense of Security!
Credits:Authors:Mazda Biria MD1,2,Ahmad Batrash, MD1,Jayasree Piallarisetti MD2, James Vacek MD2, Loren Berenbom MD2,Dhanunjaya Lakkireddy, MD2
Institutions:Medical Subspecialty Service,
Kansas City Veterans Affairs Medical Center, Kansas City, MO,Mid-America Cardiology at the University of Kansas Hospital, Kansas City, KS
Corresponding Author:Ahmad Batrash, MD,Department of Medical Subspecialties,VA medical Center,4801 Linwood Blvd,Kansas City, MO 64128, IRB Approval Number: AB0001
Keywords: Anticoagulation, Atrial fibrillation, Elderly,
Abbreviations: CAD: Coronary
Artery Disease, CNS: Central Nervous System, CVA: Cerebrovascular accident, DM:
Diabetes Mellitus, HTN: Hypertension, INR: International Normalized Ratio, KCVAMC:
Kansas City Veterans Affairs Medical Center, LVEF: Left Ventricular Ejection
Fraction TIA: Transient Ischemic Attack, AF: atrial fibrillation.
This material is the result of work
supported with resources and use of the facility at the Kansas City VA Medical
doi : 10.4022/jafib.v1i1.393
Background: Under utilization of warfarin in
elderly patients with atrial fibrillation (AF) has been recognized as a
significant health care issue. This study examines the rate and reasons for
warfarin underutilization in elderly patients with AF at the Kansas City Veterans Affairs Medical Center.
Methods: Retrospective study reviewing electronic medical
records of all patients aged 65 and older with the diagnosis of atrial
fibrillation. Patients on warfarin were excluded. Reasons for not using
warfarin were extracted by reviewing the electronic medical record.
Anticoagulation indications for these patients were determined based on the
ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial
Results:Warfarin was not used by 407
patients (25%) with known AF. Average age was 79+6.2 years. 60% of
patients had persistent or permanent AF. Prevalence of risk factors for
thromboembolism included hypertension (74%), heart failure or ejection fraction
of <40% (21%), diabetes (27%) and coronary artery disease (48%). CHADS (2)
scores were documented in the charts less than 1% of the times. Only 11
patients had CHADS (2) score of 0 and 70 had a score of 1. A class I or IIa
indication for warfarin therapy was present in 298 (73%) of patients. Return to
sinus rhythm (37%) was the most common reason for not using warfarin. In 30% of
cases the reason not to use warfarin was not addressed. Other reasons not to
use warfarin included fear of falls (7%), prior head or GI bleed (14%), patient
refusal & noncompliance (12%). History of CVA or TIA was documented in 12%
Conclusions:Underutilization of warfarin in
elderly patients with atrial fibrillation remains a common problem despite
their high risk for thromboembolic events. A false sense of security about the paroxysmal
nature of AF, lack of proper insight about stroke risk (CHADS (2)), and fear of
bleeding are the most common reasons for non use of warfarin.
fibrillation (AF) is the most common sustained arrhythmia in the elderly. Its
prevalence increases with age. It is estimated to affect over 4 percent of the
population above the age of 60[1,2]. Epidemiologic
studies show AF to be responsible for approximately 15% of strokes and
associated with decreased quality of life.
Underutilization of warfarin in elderly is a common problem ranging up to 30-60
%[4,5,6,7,8,9,10,11,12] and is
associated with an increased risk of stroke resulting in disability and
overestimating the chance of bleeding is another factor contributing to the
underuse of warfarin[ 14].
Elderly can require less warfarin to keep their INR in therapeutic range[15,16] and not paying
attention to this may increase their chance of bleeding. Study shows that
overall age is not a factor for increasing complications with warfarin but a history
of falls, a history of bleeding within the previous year and an inability to
comply with therapy were rated as important barriers to use of warfarin by 64%,
55% and 53% of physicians.
Although neurologists and internists are more involved in the care of patients
with stroke, they prescribe warfarin less frequently than cardiologists.
Kansas City Veterans Affairs Hospital (KCVA) is a tertiary care center in the
Midwest United States with large population of inpatients and outpatients. It
is an academic teaching center affiliated with the University of Kansas School
of Medicine. Pharmacists run an anticoagulation clinic and adjust the dose of
warfarin for all patients as treated. Although under use of warfarin in atrial
fibrillation is well recognized[4-12],
this study was designed to provide further insight for reasons of warfarin
underutilization in the elderly. The electronic medical record of the VA
hospital facilitated data base searches to identify subjects for this study.
patients, 65 years of age or older with atrial fibrillation between 1996 and
2006 were included in this study. Patients who were taking warfarin were excluded. The electronic records of the remaining AF patients were reviewed individually. Demographic data, reasons for stopping
or not starting warfarin, and concomitant co-morbidities were extracted.
Anticoagulation indications for these patients were assessed based on the
ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial
Fibrillation, this included class I indications based
on CHADS2 scores, as well as class IIa indications including CAD, female
gender, or age 65 to 74 years. The study and the waiver of consent were
approved by the Institutional Review Board and the Human Subject Committee.
variables are expressed as frequencies and percentages. The chance that a
patient with atrial fibrillation was not receiving warfarin was analyzed by
contingency table. Chi square was used to compare discrete data. A P
value less than 0.05 was considered significant.
thousand six hundred and thirty five (n=1635) patients 65 or older had a
diagnosis of atrial fibrillation. A total of 407 patients (25% of total) were
not using warfarin and were included in the study. Their ages ranged from 65 to
93 year old with an average age of 79 + 6.2 years. Documentation of the
type of AF was found in only 20% of charts, of them 40% of them had paroxysmal
atrial fibrillation and the remainder had persistent or permanent AF. A
diagnosis of CVA or TIA was present in 47 patients (12%), hypertension in 303
patients (74%), heart failure or impaired systolic LV function (LVEF <40%)
in 85 patients (21%), diabetes in 111 patients (27%), and coronary artery disease
in 195 patients (48%), Only 37 patients (9%) did not have a history of CVA,
TIA, hypertension, DM, or CAD (Table- 1). Frequency of CVA/TIA was 7.1% in 65-69
age group and 11.7% in 85 years of age and higher.
Table 1 Age distribution of patients with atrial fibrillation not on warfarin and concomitant co-morbidities.
patients aged 85 and older, warfarin use decreased dramatically (Figure-1). Age
was deterrent for warfarin use (P<0.001). Based on 2006 ACC/AHA/ESC
among those patients who were not on warfarin, 298 (73%) had a Class-I or
Class-IIa indication for using this agent. 42 of these patients were aged 65 to
74 years which accounted for 39% of that age group not receiving appropriate
antithrombotic medication, and 256 patients were 75 years of age or older which
accounted for 85% of that age group (p<0.001).
Figure 1 The percentages of patients with atrial fibrillation not on warfarin per total number of patients with the same diagnosis at the same age.
most common cause for not taking warfarin was being in sinus rhythm at
follow-up which accounted for 37% of the patients. Serious problems that
resulted in withholding warfarin were found in 6 patients with CNS bleeding and 2 patients with ocular bleeding. In 2 patients, warfarin was held at some point
but never restarted again for unclear reasons. Only 4 patients were documented to
have contraindication for warfarin use. Incomplete documentation was found in
27% of the patients, so we are not sure why these patients were not using
warfarin. The results are summarized in Table-2.
Table 2 Causes of stopping or not re-starting warfarin
CHADS (2) index
revealed that 14 patients had a score of 0, 93 patients had a score of 1 and
the number of patients who had scores of 2, 3, 4, 5, 6 were 162, 90, 32, 15 and
1 respectively (Table 3). Based on this data, only 107 (26.3%) patients had a
low risk for stroke in one year. CHAD (2) score was not calculated on any of
patients and were not documented as well in any of patient’s charts by physicians
who took care of these patients.
Table 3 Age distribution of CHADS (2) scores (number of subjects and percentage in each age group).
the elderly, atrial fibrillation is the single most important cause of stroke.
The risk of stroke is increased at least 6-fold in subjects with atrial
and attributable risk of atrial fibrillation for stroke approaches 30%. There
are several medications that currently are used for reducing chance of
thromboembolism in patients with atrial fibrillation. The most common of them
are aspirin and warfarin which can decrease chance of stroke. Previous studies showed
warfarin was superior to aspirin in decreasing thromboembolic events[24,25]. Substitution
of aspirin for warfarin may be considered in situations when there is
contraindication to warfarin or in very low risk patients.
In our study, only 4 patients had allergy to warfarin, 39 patients refused
taking warfarin, and non-compliance with warfarin was documented in 10
patients. All of these patients should have at least been considered for
are some data that suggest an increased risk of intracranial hemorrhage[24,26,27]or
mortality due to intracranial hemorrhage in elderly
patients on warfarin. In addition there is data that shows warfarin can
decrease ischemic stroke[24, 29]
and death[28, 29, 30].This is probably
because ischemic strokes related to atrial fibrillation tend to be more severe
in comparison to other types of strokes.
In this study only 6 patients had some kind of CNS bleeding. At the same time,
presence of CVA or TIA puts a patient in a high risk category for another
stroke. Current guidelines emphasize the use of warfarin in this subset of
patients. Nevertheless, in our study, 47
patients with a prior diagnosis of CVA or TIA were not on warfarin.
of atrial fibrillation to sinus rhythm can happen in different situations including
recurrent or paroxysmal atrial fibrillation which may be associated with
established disease states. In this study, 77 patients (51%) were not taking
warfarin because of being in sinus rhythm. A significant number of these
patients (62/77) had a CHADS 2 score of more than 2. Presence of sinus rhythm
during one of the follow up visits should not preclude physicians from offering
continued anticoagulation therapy in patients of this age group who are usually
at high risk for systemic thromboembolism. The newest practice guidelines
consider antithrombotic use as a Class-IIa indication in patients with any form
of atrial fibrillation (paroxysmal or permanent)[ 20]. Furthermore, data from AFFIRM and RACE trials
indicate that the pharmacological or electrical cardioversion to sinus rhythm
in patients with at-risk CHADS-2 scores, does not reduce the risk of stroke and
is not an indication to discontinue anticoagulation.
from this study reveal that use of warfarin dramatically drops after 85 years
of age. Previous studies have shown that the risk of thromboembolic disease
continues to increase as age goes up, as is seen in this study as well. Warfarin
has been shown to be safe in the elderly patients even in patients 90 years of
age or older when INRs are kept at target range of 2.0-3.0. Risk of falls was
documented as the reason for not taking warfarin in 7.6% of patients who were
not taking warfarin for atrial fibrillation. One study that reviewed 49
published anticoagulation trials of patients with atrial fibrillation found
that intracranial hemorrhages were uncommon. In fact the calculated risk of
subdural hematoma from falling, according to that study, is so small that a
person with an average risk of stroke from AF (5 percent/year) would have to
fall approximately 300 times in a year for the risk of anticoagulation to
outweigh its benefits[33,
nationwide trend of the use of anticoagulation in AF patients is not quite clear
at this point in time. Use of warfarin in patients with atrial fibrillation
increased from 7% in 1980 to 32% in 1993.A
study on Medicare beneficiary patients revealed that warfarin use for elderly
patients with atrial fibrillation increased from 24.5% in 1992 to 56.3% in 2002. In our
study, 75% of patients were using warfarin. But at least 10% of patients with
atrial fibrillation who met class-I indication for warfarin use were not on
several advantages of electronic medical record in the VA system and access of
health care providers to the patient’s health data in a short fraction of time,
still 2.5% of subjects were not receiving warfarin due to communication errors.
We could not find another study that looked at the same problem in subjects
with atrial fibrillation. And it also shows that VA’s electronic system has
potential for improvements if it can alert health care providers for these
study was performed retrospectively by using medical records on patients with a
documented diagnosis of atrial fibrillation. We did not examine the accuracy of
the diagnosis. Incomplete documentation poses some limitations on data
interpretation as well. We did not include INR values in this study which may
reflect patient compliance with the medication and follow up. Also we did not
include aspirin in our record review since documentation of its use was
expected to be significantly less accurate since most VA patients buy aspirin
over the counter. Only 5 patients were female which represents a typical VA population.
Gender does not change Class-I indication for warfarin use but has a small role
in Class-IIa indications. This study was not designed to compare
subjects who were on warfarin with those who are not taking warfarin since we
believe that all patients with atrial fibrillation have a higher thrombotic
rate in compare to normal population.
of warfarin in elderly patients with atrial fibrillation remains a common
problem despite their high risk for thromboembolic events. A false sense of
security about the paroxysmal nature of atrial fibrillation, lack of proper
insight about stroke risk (CHADS2), and fear of bleeding are the most common
reasons for non use of warfarin.
1. Halperin JL; Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke 1988 Aug;19(8):937-41
2. Kannel WB; Abbott RD; Savage DD; McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982 Apr 29;306(17):1018-22
3. Ezekowitz MD, Netrebko PI. Anticoagulation in management of atrial fibrillation. Curr Opin Cardiol. 2003 Jan;18(1):26-31.CrossRef PubMed
4. Frykman V, Beerman B, Ryden L, Rosenqvist M. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J. 2001 Oct;22(20):1954-9.CrossRef PubMed
5.McCormick D, Gurwitz JH, Goldberg RJ, Becker R, Tate JP, Elwell A, Radford MJ. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting.Arch Intern Med. 2001 Nov 12;161(20):2458-63.CrossRef PubMed
6. Ruigomez A, Johansson S, Wallander MA, Rodriguez LA. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol. 2002 Apr;55(4):358-63.CrossRef PubMed
7.Ono A, Fujita T. Stroke prevention in patients with atrial fibrillation. J Clin Neurosci. 2003 Jan;10(1):71-3.CrossRef PubMed
8. Nagpal S, Anderson D, Putnam W, Flowerdew G, Gardner M, Cox J. Stroke prevention in hospitalized patients with atrial fibrillation: a population-based study. Can J Clin Pharmacol. 2003 Winter;10(4):197-201
9. Lau E, Bungard TJ, Tsuyuki RT. Stroke prophylaxis in institutionalized elderly patients with atrial fibrillation. J Am Geriatr Soc. 2004 Mar;52(3):428-33.CrossRef PubMed
10.White S, Feely J, O'Neill D. Community-based study of atrial fibrillation and stroke prevention. Ir Med J. 2004 Jan;97(1):10-2
11. Blich M, Gross B. Thromboembolic prophylaxis in nonrheumatic atrial fibrillation: utilization patterns, efficacy, and complications in a long-term follow-up of community patients. Int J Cardiol. 2004 Jul;96(1):89-95.CrossRef PubMed
12. Marcu CB, Ghantous AE, Caracciolo EA, Donohue TJ. Patterns of anticoagulation in patients hospitalized with atrial fibrillation: warfarin is underused in paroxysmal atrial fibrillation. Con Med. 2003 Nov-Dec;67(10):595-8
13.Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004 Dec;10(14 Suppl):S451-58
14.Gross CP, Vogel EW, Dhond AJ, Marple CB, Edwards RA, Hauch O, Demers EA, Ezekowitz M. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther. 2003 Jun;25(6):1750-64.CrossRef PubMed
15.Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005 Jun;127(6):2049-56.CrossRef PubMed
16.Singla DL, Morrill GB. Warfarin maintenance dosages in the very elderly. Am J Health Syst Pharm. 2005 May 15;62(10):1062-6
17.Putnam W, Nicol K, Anderson D, Brownell B, Chiasson M, Burge FI, Flowerdew G, Cox J. Anticoagulation in atrial fibrillation. Is there a gap in care for ambulatory patients? Can Fam Physician. 2004 Sep;50:1244-50
18.Bungard TJ, Ghali WA, McAlister FA, Buchan AM, Cave AJ, Hamilton PG, Mitchell LB, Shuaib A, Teo KK, Tsuyuki RT. The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Can J Cardiol. 2003 Mar 15;19(3):280-4
19.Rahimi AR, Wrights B, Akhondi H, Richard CM. Clinical correlation between effective anticoagulants and risk of stroke: are we using evidence-based strategies? South Med J. 2004 Oct;97(10):924-31.CrossRef PubMed
20. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc J-J, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:e149 –246.PubMed
21.Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70.CrossRef PubMed
22.Ferro JM. Atrial fibrillation and cardioembolic stroke. Minerva Cardioangiol. 2004 Apr;52(2):111-24
23.Ezekowitz MD, Falk RH. The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Mayo Clin Proc. 2004 Jul;79(7):904-13
24.Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003 Nov 26;290(20):2685-92.CrossRef PubMed
25.Evans A, Perez I, Yu G, Kalra L. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke. 2001 Dec 1;32(12):2828-32.CrossRef PubMed
26.Karni A, Holtzman R, Bass T, Zorman G, Carter L, Rodriguez L, Bennett-Shipman VJ, Lottenberg L. Traumatic head injury in the anticoagulated elderly patient: a lethal combination. Am Surg. 2001 Nov;67(11):1098-100
27.Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004 Apr 26;164(8):880-4.CrossRef PubMed
28.Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005 Jun;118(6):612-7.CrossRef PubMed
29.Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003 Sep 11;349(11):1019-26.CrossRef PubMed
30.Tsivgoulis G, Spengos K, Zakopoulos N, Manios E, Peppes V, Vemmos K. Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study. Age Ageing. 2005 Jan;34(1):35-40.CrossRef PubMed
31. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003 Mar-Apr;22(2):118-23.CrossRef PubMed
32.Joffe HV, Goldhaber SZ. Effectiveness and safety of long-term anticoagulation of patients >/=90 years of age with atrial fibrillation.Am J Cardiol. 2002 Dec 15;90(12):1397-8.CrossRef PubMed
33.Man-Son-Hing, M, Nichol, G, Lau, A, Laupacis, A. Choosing antithrombotic therapy for elderly patients with atrila fibrillation who are at risk for falls. Arch Intern Med 1999; 159:677.CrossRef PubMed
34.Man-Son-Hing, M, Laupacis, A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians’s fears often unfounded. Arch Intern Med 2003; 163:1580.CrossRef PubMed
35.Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996 Dec 9-23;156(22):2537-41.CrossRef PubMed
36.Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002). Stroke. 2006 Aug;37(8):1969-74.CrossRef PubMed